Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Antiangiogenesis and anticancer efficacy of TA138, a novel alphavbeta3 antagonist.

Mousa SA, Mohamed S, Wexler EJ, Kerr JS.

Anticancer Res. 2005 Jan-Feb;25(1A):197-206.

2.

Antisense oligonucleotides selectively regulate aspartyl beta-hydroxylase and its truncated protein isoform in vitro but distribute poorly into A549 tumors in vivo.

Ho SP, Scully MS, Krauthauser CM, Wexler EJ, Stow MD, Dinchuk JE, Kerr JS, Friedman PA.

J Pharmacol Exp Ther. 2002 Aug;302(2):795-803.

3.

An objective procedure for ischemic area evaluation of the stroke intraluminal thread model in the mouse and rat.

Wexler EJ, Peters EE, Gonzales A, Gonzales ML, Slee AM, Kerr JS.

J Neurosci Methods. 2002 Jan 15;113(1):51-8.

PMID:
11741721
4.

Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.

Wexler EJ, Gravallese EM, Czerniak PM, Devenny JJ, Longtine J, Wong MK, Slee AM, Kerr JS.

Clin Cancer Res. 2000 Aug;6(8):3361-70.

5.

Novel small molecule alpha v integrin antagonists: comparative anti-cancer efficacy with known angiogenesis inhibitors.

Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A Jr, Slee AM.

Anticancer Res. 1999 Mar-Apr;19(2A):959-68.

PMID:
10368639
6.

A fluorescent cellular adhesion assay using insect cell produced human VCAM1.

Stoltenborg JK, Tsao PW, George HJ, Bouchard PJ, Wexler EJ, Hausner EA.

J Immunol Methods. 1994 Sep 30;175(1):59-68.

PMID:
7523526

Supplemental Content

Loading ...
Support Center